Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Biogen Inc(BIIB)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BIIB
11/06/2026: BIIB (4-star) is a STRONG-BUY. BUY for 129 days. Simulated Profits (30.24%). Updated daily EoD!
Biogen Inc is a specialized biotechnology firm focusing on neurological and rare diseases. The company is currently navigating a pivotal transition, balancing declining revenue from its legacy multiple sclerosis franchise with the high-stakes commercial rollout of its new Alzheimer's therapy, Leqembi. Its primary strength lies in its deep scientific expertise in neuroscience, while its main opportunity rests on successfully expanding the reach of its newer assets. Key risks include intense competition, clinical development hurdles, and regulatory uncertainties regarding drug pricing and reimbursement. The stock is generally better suited for growth-oriented investors with a higher risk tolerance, and those monitoring development should watch for ongoing commercial data for Leqembi.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Growth is highly dependent on the success of new product launches in the volatile Alzheimer's market. |
| Momentum investor | Strong fit while signal remains positive | Momentum investors may find opportunities during positive news cycles regarding clinical trial successes or regulatory approvals. |
| Value investor | Mixed fit | The company's valuation is tied to the success of its pipeline, making traditional value metrics difficult to apply. |
| Dividend investor | Weak fit | Biogen does not pay a dividend, making it unsuitable for income-focused portfolios. |
| Low-risk investor | Weak fit | Clinical and regulatory risks associated with drug development create significant price volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical trial outcomes and FDA decisions can lead to sharp swings in share price. |
| Valuation risk | Medium | Future growth expectations are baked into the stock price, leaving little margin for error. |
| Competition risk (Neurology drug market) | High | Major competitors like Eli Lilly are aggressively targeting the same high-value Alzheimer's indications. |
| Business quality | Medium / high | While the franchise is specialized, reliance on a narrow therapeutic area creates concentration risk. |
| Dividend income | Low / none | There is no dividend income stream for shareholders. |
| Execution risk | High | Successfully launching new, complex therapies requires flawless execution against established competitors. |
Price Behavior
Hockey-Stick Growth
The stock demonstrates a Hockey-Stick Growth price path pattern.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 20.72% | Avg. Invested days 66 | Today’s Advisory Strong Buy |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/06/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 36.71B USD | Price to earnings Ratio 107.51 | 1Y Target Price 266.39 |
Price to earnings Ratio 107.51 | 1Y Target Price 266.39 | ||
Volume (30-day avg) 1.3M shares | Beta 0.09 | 52 Weeks Range 153.77 - 258.78 | Updated Date 11/08/2026 |
52 Weeks Range 153.77 - 258.78 | Updated Date 11/08/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.31 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Product Revenue | Sales of Tysabri, Spinraza, Leqembi, and other neurology/rare disease products. | The company makes money by selling specialty drugs to treat complex, often life-altering neurological conditions. |
| Royalties and Contract Revenue | Revenue from licensing agreements and manufacturing arrangements for biosimilars. | Secondary income flows from partnerships and sharing in the success of licensed technologies. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-10-28 | When Before Market | Estimate 2.06 | Actual 2.62 |
Profitability
Profit Margin 3.38% | Operating Margin (TTM) 24.12% |
Management Effectiveness
Return on Assets (TTM) 4.94% | Return on Equity (TTM) 1.87% |
Valuation
Trailing PE 107.51 | Forward PE 16.08 | Enterprise Value 43.21B | Price to Sales(TTM) 3.57 |
Enterprise Value 43.21B | Price to Sales(TTM) 3.57 | ||
Enterprise Value to Revenue 4.2 | Enterprise Value to EBITDA 26.48 | Shares Outstanding 147.82M | Shares Floating 147.29M |
Shares Outstanding 147.82M | Shares Floating 147.29M | ||
Percent Insiders 0.19 | Percent Institutions 100.07 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.